Fig. 2From: Future options of anti-angiogenic cancer therapyAnti-angiogenic drug targets. Monospecific bevacizumab, 2–3-targeted aflibercept and ramucirumab, and multi-targeted tyrosine kinase inhibitor anti-angiogenic drugs are currently used to treat cancer in human patientsBack to article page